Takeda Pharmaceutical (TAK) EBIT Growth (3y) (2020 - 2026)
Takeda Pharmaceutical (TAK) EBIT Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -59.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.90% |
| Mar 31, 2026 | 0.25% |
| Dec 31, 2025 | -66.30% |
| Sep 30, 2025 | 55.93% |
| Jun 30, 2025 | 3.10% |
| Mar 31, 2025 | -17.30% |
| Dec 31, 2024 | -35.37% |
| Sep 30, 2024 | 46.78% |
| Jun 30, 2024 | -22.22% |
| Mar 31, 2024 | -7.17% |
| Dec 31, 2023 | -24.08% |
| Sep 30, 2023 | 82.89% |
| Jun 30, 2023 | -7.52% |
| Mar 31, 2023 | -21.14% |
| Sep 30, 2022 | 8.31% |
| Jun 30, 2022 | 41.50% |
| Mar 31, 2022 | 1,163.34% |
| Dec 31, 2021 | 0.92% |
| Sep 30, 2021 | -88.95% |
| Jun 30, 2021 | 35.79% |